CCND1 and Alzheimer disease: We detected that treatment with AD and ERK1/2 inhibitor U0126 increased p27 protein expression and reduced the expression of cyclin D1 and cyclin E proteins in VSMCs exposed to ox-LDL, suggesting that treatment with AD and ERK1/2 blocker upregulated p27 expression and inhibited cyclin D1 and cyclin E expressions, which may be linked to miR-17∼92a cluster expression.